NeoCOAST-2 study links ctDNA clearance to longer event-free survival in resectable lung cancer
A Phase 2 study reported that ctDNA clearance during treatment was associated with longer event-free survival in patients with resectable non-small cell lung cancer.
A Nature report on the NeoCOAST-2 Phase 2 trial examined 202 patients with stage IIA to IIIB resectable non-small cell lung cancer who received perioperative treatment combinations. The study reported 24-month event-free survival rates ranging from 70.5% to 77.9% across three treatment groups.
The researchers reported that clearance of circulating tumor DNA before surgery was associated with longer event-free survival. They said the findings support further study of ctDNA clearance and pathological response for risk assessment, rather than establishing a new standard of care.